Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 1, 2005

View Archived Issues

Avicinylation helps fight oxidative and nitrosative stress

Update on the efficacy of once-weekly exenatide LAR in type 2 diabetes

New clinical evidence supports the use of oxymorphone ER in chronic pain

MedImmune licenses rights from GSK to BSYX-A110

Long-term benefits of rimonabant in overweight/obese patients

TAP Pharmaceutical to develop Takeda's TAK-390MR for acid disorders

Cardiome Pharma to acquire Artesian Therapeutics

NeuroSearch and TopoTarget expand collaboration with NSD-551

PDE4 inhibitor GRC-3886 named oglemilast, set to enter phase II in 2006

Nippon Chemiphar and Cerenis sign license agreement for PPARdelta agonists

Early close out of SIMPADICO trial of Celcade

Pivotal study begins for CPI-226 for prevention of catheter-related infections

Enrollment 90% complete in phase IIIb malignant mesothelioma study of Onconase

Amplimexon receives U.S. orphan drug status for ovarian cancer

CGX-1160 designated orphan drug for chronic intractable pain

Modulation of plasminogen pathways may cause rofecoxib-associated cardiovascular complications

GW-493838X: preclinical and clinical update

New title added to the Drug R&D Backgrounders topic list - Actinic Keratosis

Final results from the PROMPT study confirm the benefits of epoetin alfa in CKD patients with anemia

Belatacept found as effective and better tolerated than ciclosporin in renal transplant recipients

Isatoribine induces antiviral effects in patients with chronic hepatitis C

Bristol Myers seeks Japanese approval for Baraclude

Increlex approved for short stature caused by severe primary IGF-1 deficiency

New clinical data supports the use of methylnaltrexone in opioid-induced constipation

sBLA filing for Rituxan in rheumatoid arthritis

Recent patents cover novel treatments for psychiatric disorders

Novel therapeutics for neurological disorders reported in recent patent literature

GABA-B receptor agonists prepared and tested at Bayer

Novel selective alpha4beta7/MAdCAM-1 antagonist reduces inflammation in mice with colitis

XEN-2174: efficacious against morphine tolerant neuropathic and incisional pain

Novel PPARgamma inverse agonist GSK-5737 effective in preclinical models of diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...